Zontivity
| Chemical Name | vorapaxar |
| Dosage Form | Tablet (oral; 2.08 mg) |
| Drug Class | Receptor antagonists |
| System | Cardiovascular |
| Company | Xspire Pharmaceuticals |
| Approval Year | 2014 |
Indication
- Indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).